IN2012DN02596A - - Google Patents

Info

Publication number
IN2012DN02596A
IN2012DN02596A IN2596DEN2012A IN2012DN02596A IN 2012DN02596 A IN2012DN02596 A IN 2012DN02596A IN 2596DEN2012 A IN2596DEN2012 A IN 2596DEN2012A IN 2012DN02596 A IN2012DN02596 A IN 2012DN02596A
Authority
IN
India
Prior art keywords
activity
molecules
protein kinase
kinase
relates
Prior art date
Application number
Other languages
English (en)
Inventor
Fabirce PIERRE
Mustapha Haddach
Collin F Regan
David M Ryckman
Original Assignee
Cylene Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cylene Pharmaceuticals Inc filed Critical Cylene Pharmaceuticals Inc
Publication of IN2012DN02596A publication Critical patent/IN2012DN02596A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • A61P33/12Schistosomicides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
IN2596DEN2012 2009-08-26 2010-08-26 IN2012DN02596A (US06268391-20010731-C00042.png)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23722709P 2009-08-26 2009-08-26
US28931709P 2009-12-22 2009-12-22
PCT/US2010/046760 WO2011025859A1 (en) 2009-08-26 2010-08-26 Condensed quinolines as protein kinase modulators

Publications (1)

Publication Number Publication Date
IN2012DN02596A true IN2012DN02596A (US06268391-20010731-C00042.png) 2015-08-28

Family

ID=42983433

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2596DEN2012 IN2012DN02596A (US06268391-20010731-C00042.png) 2009-08-26 2010-08-26

Country Status (13)

Country Link
US (1) US20110065698A1 (US06268391-20010731-C00042.png)
EP (1) EP2470544A1 (US06268391-20010731-C00042.png)
JP (1) JP2013503178A (US06268391-20010731-C00042.png)
KR (1) KR20120059571A (US06268391-20010731-C00042.png)
CN (1) CN102596969A (US06268391-20010731-C00042.png)
AU (1) AU2010286691A1 (US06268391-20010731-C00042.png)
BR (1) BR112012004304A2 (US06268391-20010731-C00042.png)
CA (1) CA2771890A1 (US06268391-20010731-C00042.png)
IL (1) IL218280A0 (US06268391-20010731-C00042.png)
IN (1) IN2012DN02596A (US06268391-20010731-C00042.png)
MX (1) MX2012002426A (US06268391-20010731-C00042.png)
SG (1) SG178552A1 (US06268391-20010731-C00042.png)
WO (1) WO2011025859A1 (US06268391-20010731-C00042.png)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
BR112015016793B1 (pt) 2013-01-15 2021-12-28 Incyte Holdings Corporation Compostos de tiazolacarboxamidas e piridinacarboxamida, composição compreendendo os mesmos, método de inibição da enzima pim1, pim2, ou pim3, e usos dos referidos compostos
US9556197B2 (en) 2013-08-23 2017-01-31 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
BR112020000083A2 (pt) * 2017-07-03 2020-07-07 Bayer Cropscience Aktiengesellschaft novas isotiazolopiridonas substituídas, processos para sua preparação e seu uso como herbicidas e/ou reguladores de crescimento da planta
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
US11071727B2 (en) 2018-01-26 2021-07-27 Northwestern University Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors
WO2023126951A1 (en) * 2022-01-03 2023-07-06 Yeda Research And Development Co. Ltd. Inhibitors of autophagy-related protein-protein interactions
GB202213163D0 (en) * 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213166D0 (en) * 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
ATE339406T1 (de) 1999-09-23 2006-10-15 Astrazeneca Ab Chinazoline verbindungen als heilmittel
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
BRPI0607748A2 (pt) 2005-02-17 2017-05-23 Amr Tech Inc composto, composição farmacêutica, e, método de tratamento de um distúrbio
CA2974246C (en) * 2006-09-01 2020-02-25 Senhwa Biosciences, Inc. Tricyclic heteroaryl compounds and their use as protein modulators
JP2011515337A (ja) * 2008-02-29 2011-05-19 サイレーン ファーマシューティカルズ, インコーポレイテッド プロテインキナーゼモジュレーター
KR20110095857A (ko) * 2008-09-10 2011-08-25 칼립시스, 인코포레이티드 질환의 치료를 위한 히스타민 수용체의 헤테로시클릭 억제제
TW201204727A (en) * 2010-03-10 2012-02-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease

Also Published As

Publication number Publication date
BR112012004304A2 (pt) 2016-03-15
JP2013503178A (ja) 2013-01-31
KR20120059571A (ko) 2012-06-08
SG178552A1 (en) 2012-03-29
CN102596969A (zh) 2012-07-18
US20110065698A1 (en) 2011-03-17
CA2771890A1 (en) 2011-03-03
EP2470544A1 (en) 2012-07-04
AU2010286691A1 (en) 2012-04-19
WO2011025859A1 (en) 2011-03-03
MX2012002426A (es) 2012-06-27
IL218280A0 (en) 2012-04-30

Similar Documents

Publication Publication Date Title
IN2012DN02596A (US06268391-20010731-C00042.png)
MX2009002298A (es) Moduladores de serina-treonina proteina quinasa y de parp.
MX341591B (es) Inhibidores de cinasa de benzoxazol y metodos de uso de los mismos.
PH12015501370A1 (en) Compounds and methods for kinase modulation, and indications therefor
WO2010006086A3 (en) Kinase inhibitors and methods of use
MY168757A (en) Novel compounds as modulators of protein kinases
UA97816C2 (en) Compounds modulating c-kit and/or c-fms activity and use thereof
EA200901308A1 (ru) Ингибиторы белка, активирующего 5-липоксигеназу (flap)
MX2009012623A (es) Moduladores de cinasa heterociclicos.
MY148468A (en) Compounds and methods for kinase modulation, and indications therefor
MX2009006688A (es) Compuestos y metodos para modulacion de cinasas, e indicaciones para ello.
EA201490695A1 (ru) Слитые белки для лечения нарушений метаболизма
EA201290209A1 (ru) Новые модуляторы бензопиран киназы
BR112014023162A8 (pt) compostos e métodos para modulação quinase e indicações dos mesmos
WO2011090738A3 (en) Type ii raf kinase inhibitors
WO2009097014A3 (en) Therapeutic kinase modulators
EA200970729A1 (ru) Варианты, происходящие из actriib, и их применение
WO2009044173A3 (en) Methods of treating cancer using notch pathway inhibitors
MY162950A (en) Compounds and methods for kinase modulation, and indications therefor
GT200600254A (es) Moduladores de aminoquinolina y aminoquinazolina quinasa
PH12016500432A1 (en) Inhibitors of erk and methods of use
GB2535937A (en) Methods and compositions for modulating the immune system with Arginase I
UA101814C2 (ru) Фактор, задействованный в латентной инфекции герпесвирусом, и его применение
EP2563794A4 (en) INHIBITORS OF TYROSINE KINASE PROTEIN ACTIVITY AND THEIR APPLICATIONS TO THE TREATMENT OF OPHTHALMIC DISORDERS
IN2014DN03295A (US06268391-20010731-C00042.png)